NASDAQ · XENE
Xenon Pharmaceuticals Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for XENE: Nov 2, 2026
Xenon Pharmaceuticals Inc. Common Shares is estimated to report earnings on 11/02/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 8 analysts' forecasts, the consensus EPS forecast for the quarter is $-1.17. The reported EPS for the same quarter last year was $-1.15.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-1.17 | $-0.98 | $-1.36 | 8 |
| Dec 2026 | $-1.16 | $-1.04 | $-1.29 | 7 |
| Mar 2027 | $-1.24 | $-1.17 | $-1.35 | 4 |
| Jun 2027 | $-1.25 | $-1.15 | $-1.43 | 4 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · Zacks · BNK Invest · MarketBeat- RTTNews · Oct 29, 12:44 PM EDTXenon Reports Promising Pain Data, Targets Phase 2 Trials For Two Drug Candidates(RTTNews) – Xenon Pharmaceuticals Inc. (XENE) announced positive Phase 1 results and new preclinical data supporting the advancement of its investigational pain candidates XEN1701 and XEN1120 to Phase 2 proof-of-concept studies in acute pain.
- Zacks · Oct 15, 12:05 PM EDTXENE's Depression Trial Setback: Is Its Pipeline Still Attractive?Xenon pauses enrollment in late-stage depression trials after unexpected side effects, while its epilepsy pipeline offers growth potential.
- BNK Invest · Oct 1, 11:40 AM EDTThursday 10/1 Insider Buying Report: XENEAs the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy — they expect to make money. So let's look at one noteworthy recent insider buy. At Xenon Pharmaceuticals, there was insider buying on Wednesday, by Chief Financial
- MarketBeat · Sep 27, 12:02 PM EDTXenon Files Azetukalner NDA as It Pauses Psychiatry Trials for Tolerability ReviewBristol Myers Squibb’s big buys: $18.1 billion in 2 biotech dealsXenon Pharmaceuticals (NASDAQ:XENE) said it has filed its first new drug application for azetukalner as a treatment for focal-onset seizures, while pausing portions of its late-stage psychiatry program to evaluate c
- Barchart · Sep 21, 2:17 PM EDTStocks Finish Mostly Higher as Crude Prices FallThe S&P 500 Index ($SPX ) (SPY ) closed up by +0.17% on Friday, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed down by -0.18%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.67%. December E-mini S&P futures (ESZ26 ) rose +0.20%, and December E-mini…
- Barchart · Sep 18, 7:29 PM EDTStocks Waver as Bond Yields ClimbThe S&P 500 Index ($SPX ) (SPY ) is down by -0.11% today, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down by -0.39%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.09%. December E-mini S&P futures (ESZ26 ) are down -0.15%, and December E-mini…
- Barchart · Sep 18, 7:29 PM EDTStocks Mixed as Crude Oil Prices and Bond Yields RiseThe S&P 500 Index ($SPX ) (SPY ) is down by -0.03% today, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down by -0.23%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.20%. December E-mini S&P futures (ESZ26 ) are down -0.05%, and December E-mini…
- Zacks · Sep 18, 11:09 AM EDTXENE Files NDA for Epilepsy Drug, Falls on Depression Studies' SetbackXenon files an FDA application for azetukalner in epilepsy as its depression studies face a temporary enrollment pause.
- RTTNews · Sep 18, 1:21 AM EDTXenon Pharma Tumbles On Azetukalner Psychiatry Trial Enrollment Pause; Files Focal Seizure NDA(RTTNews) – Shares of Xenon Pharmaceuticals Inc. (XENE) are plunging over 25% in the after-hours market after the neuroscience-focused biopharmaceutical company announced that it has voluntarily paused new patient enrollment in ongoing Phase 3 studies of azetukalner for major dep
- The Motley Fool · Aug 13, 5:58 PM EDTXenon Pharmaceuticals (XENE) Q2 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- MarketBeat · Aug 7, 4:04 PM EDTXenon Pharmaceuticals Q2 Earnings Call HighlightsBristol Myers Squibb’s big buys: $18.1 billion in 2 biotech deals10x Genomics reported second-quarter revenue of $151 million, including $1.6 million in license and royalty revenue tied to its settlement with Takara Bio. Excluding non-recurring settlement revenue in both periods,
- Zacks · Aug 7, 10:12 AM EDTXENE's Q2 Loss Narrower Than Expected, Sales Nil, Pipeline in FocusXenon posts a narrower-than-expected Q2 loss as azetukalner advances toward a planned FDA filing, while its cash runway is expected to support operations into 2029.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Xenon Pharmaceuticals Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.